Navigation Links
Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
Date:3/31/2009

TEMPE, Ariz., March 31 /PRNewswire/ -- Intrinsic Bioprobes, Inc. today announced the start of a contract with the National Cancer Institute to develop effective technologies for accurate measurement of cancer-related proteins and peptides that improve diagnostic capabilities by effectively discerning diseased from non-diseased states. The total cost of the two-and-a-half-year contract is $1,276,360, out of which $1,130,272 is Federal money provided by the NCI, and $146,088 is the contractor's share provided by Intrinsic Bioprobes, Inc. This contract is in support of NCI's Clinical Proteomic Technologies for Cancer initiative to assess and apply proteomic technologies and data resources to solve critical problems in cancer research (http://proteomics.cancer.gov).

"The purpose of this contract is to stimulate the development of multiplex mass spectrometric immunoassay for the detection of low abundance cancer-related proteins/peptides from bodily fluids," says Dobrin Nedelkov, Ph.D., the Scientific Director of Intrinsic Bioprobes. "The application of proteomics tools in the clinical setting lags far behind their use in basic science and drug discovery. The multiplex mass spectrometric immunoassays will bridge that gap because they are highly specific and selective, have ultra-sensitive detection capabilities and broad dynamic range, and require limited sample preparation. The mass spectrometric aspect of the assays also enables single-step detection of protein isoforms and their individual quantification, which is an important protein diversity aspect regularly overlooked in contemporary proteomics approaches," adds Nedelkov.

Intrinsic Bioprobes, Inc. is a privately held Biotechnology Company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay, a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high-throughput analysis of proteins from complex biological matrices, and Bioreactive Mass Spectrometer Probes, devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high-throughput mass spectrometry platform for rapid proteome analysis. For more information about Intrinsic Bioprobes, Inc., please visit http://www.intrinsicbio.com.

    Contact:

    Intrinsic Bioprobes, Inc.
    Tel.: (480) 804-1778
    E-mail: info@intrinsicbio.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Intrinsic Bioprobes, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
2. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
3. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
4. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
5. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
6. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
7. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
8. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
9. Elbit Medical Imaging Ltd. Announces that Plaza Centers Has Entered into a Joint Venture Partnership to Develop Residential and Office Projects in Romania
10. Sangui Partnership Enters a New Phase:
11. Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... ... announced that the stock market news outlet had initiated coverage on Interpace ... that screens and identifies exposure, progression and risk analysis from specific cancers ...
(Date:7/20/2017)... ... 2017 , ... Resoundant, Inc. is pleased to introduce ... U.S. that offer MR Elastography for liver fibrosis staging. MR Elastography is ... liver fibrosis assessment. , “MRE:connect was created in response to an increasing number ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... of life, today announced its full advisory board. The board comprises leaders spanning ... of James Crooks, PhD, former VP of Engineering, to Chief Technology Officer. Crooks ...
(Date:7/20/2017)... ... July 20, 2017 , ... Corista, a leader in integrated ... Tuesday, July 25, during the Association of Pathology Chairs’ Jubilee Meeting in Washington, ... Baras, Associate Director of Pathology Informatics, will present “The Digital Pathology Experience at ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
Breaking Biology News(10 mins):